Evidence map›Paper›PMID 31918577›Full record

ArticleCirculation2020

Small Extracellular Microvesicles Mediated Pathological Communications Between Dysfunctional Adipocytes and Cardiomyocytes as a Novel Mechanism Exacerbating Ischemia/Reperfusion Injury in Diabetic Mice.

Lu Gan, Dina Xie, Jing Liu, Wayne Bond Lau, Theodore A Christopher, Bernard Lopez, Ling Zhang, Erhe Gao, Walter Koch, Xin-Liang Ma and 1 more

Open access · greenAbstract read
In one paragraph

Article in Circulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 210 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Lu GanDepartment of Emergency Medicine and Medicine, Thomas Jefferson University, Philadelphia, PA (L.G., D.X., J.L, W.B.L., T.A.C., B.L., L.Z., X.-L.M., Y.W.).
Dina XieDepartment of Emergency Medicine and Medicine, Thomas Jefferson University, Philadelphia, PA (L.G., D.X., J.L, W.B.L., T.A.C., B.L., L.Z., X.-L.M., Y.W.).
Jing LiuDepartment of Emergency Medicine and Medicine, Thomas Jefferson University, Philadelphia, PA (L.G., D.X., J.L, W.B.L., T.A.C., B.L., L.Z., X.-L.M., Y.W.).
Wayne Bond LauDepartment of Emergency Medicine and Medicine, Thomas Jefferson University, Philadelphia, PA (L.G., D.X., J.L, W.B.L., T.A.C., B.L., L.Z., X.-L.M., Y.W.).
Theodore A ChristopherDepartment of Emergency Medicine and Medicine, Thomas Jefferson University, Philadelphia, PA (L.G., D.X., J.L, W.B.L., T.A.C., B.L., L.Z., X.-L.M., Y.W.).
Bernard LopezDepartment of Emergency Medicine and Medicine, Thomas Jefferson University, Philadelphia, PA (L.G., D.X., J.L, W.B.L., T.A.C., B.L., L.Z., X.-L.M., Y.W.).
Ling ZhangDepartment of Emergency Medicine and Medicine, Thomas Jefferson University, Philadelphia, PA (L.G., D.X., J.L, W.B.L., T.A.C., B.L., L.Z., X.-L.M., Y.W.).
Erhe GaoCenter for Translational Medicine, Temple University, Philadelphia, PA (E.G., W.K.).
Walter KochCenter for Translational Medicine, Temple University, Philadelphia, PA (E.G., W.K.).
Xin-Liang MaDepartment of Emergency Medicine and Medicine, Thomas Jefferson University, Philadelphia, PA (L.G., D.X., J.L, W.B.L., T.A.C., B.L., L.Z., X.-L.M., Y.W.).
Yajing WangDepartment of Emergency Medicine and Medicine, Thomas Jefferson University, Philadelphia, PA (L.G., D.X., J.L, W.B.L., T.A.C., B.L., L.Z., X.-L.M., Y.W.).
Thomas Jefferson University · USTemple University · US

Funding

Targeting Adiponectin for Cardioprotection in the Ischemic HeartR01HL096686 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI MA, XIN-LIANG, WANG, YAJING · 2010 to 2024
$4.7M
Cav-3 in Diabetic Myocardial Injury Following Ischemia/ReperfusionR01HL123404 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI MA, XIN-LIANG · 2015 to 2023
$2.7M
Vevo 3100 ultrasound scanner and PV loop systemS10OD030483 · OD · THOMAS JEFFERSON UNIVERSITY · PI FORSBERG, FLEMMING · 2021 to 2021
$747k
Vevo 2100 ultrasound scannerS10OD010408 · OD · THOMAS JEFFERSON UNIVERSITY · PI FORSBERG, FLEMMING · 2012 to 2012
$525k
Cav-3 in Diabetic Myocardial Injury Following Ischemia/ReperfusionR56HL123404 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI MA, XIN-LIANG · 2014 to 2014
$388k
NHLBI NIH HHS R01 HL096686NHLBI NIH HHS R01 HL123404NHLBI NIH HHS R56 HL123404NIH HHS S10 OD010408NIH HHS S10 OD030483
6 · The paper itself

Abstract

backgroundDiabetes mellitus exacerbates myocardial ischemia/reperfusion (MI/R) injury by incompletely understood mechanisms. Adipocyte dysfunction contributes to remote organ injury. However, the molecular mechanisms linking dysfunctional adipocytes to increased MI/R injury remain unidentified. The current study attempted to clarify whether and how small extracellular vesicles (sEV) may mediate pathological communication between diabetic adipocytes and cardiomyocytes, exacerbating MI/R injury.

methodsAdult male mice were fed a normal or a high-fat diet for 12 weeks. sEV (from diabetic serum, diabetic adipocytes, or high glucose/high lipid-challenged nondiabetic adipocytes) were injected intramyocardially distal of coronary ligation. Animals were subjected to MI/R 48 hours after injection.

resultsIntramyocardial injection of diabetic serum sEV in the nondiabetic heart significantly exacerbated MI/R injury, as evidenced by poorer cardiac function recovery, larger infarct size, and greater cardiomyocyte apoptosis. Similarly, intramyocardial or systemic administration of diabetic adipocyte sEV or high glucose/high lipid-challenged nondiabetic adipocyte sEV significantly exacerbated MI/R injury. Diabetic epididymal fat transplantation significantly increased MI/R injury in nondiabetic mice, whereas administration of a sEV biogenesis inhibitor significantly mitigated MI/R injury in diabetic mice. A mechanistic investigation identified that miR-130b-3p is a common molecule significantly increased in diabetic serum sEV, diabetic adipocyte sEV, and high glucose/high lipid-challenged nondiabetic adipocyte sEV. Mature (but not primary) miR-130b-3p was significantly increased in the diabetic and nondiabetic heart subjected to diabetic sEV injection. Whereas intramyocardial injection of a miR-130b-3p mimic significantly exacerbated MI/R injury in nondiabetic mice, miR-130b-3p inhibitors significantly attenuated MI/R injury in diabetic mice. Molecular studies identified AMPKα1/α2, Birc6, and Ucp3 as direct downstream targets of miR-130b-3p. Overexpression of these molecules (particularly AMPKα2) reversed miR-130b-3p induced proapoptotic/cardiac harmful effect. Finally, miR-130b-3p levels were significantly increased in plasma sEV from patients with type 2 diabetes mellitus. Incubation of cardiomyocytes with diabetic patient sEV significantly exacerbated ischemic injury, an effect blocked by miR-130b-3p inhibitor.

conclusionsWe demonstrate for the first time that miR-130b-3p enrichment in dysfunctional adipocyte-derived sEV, and its suppression of multiple antiapoptotic/cardioprotective molecules in cardiomyocytes, is a novel mechanism exacerbating MI/R injury in the diabetic heart. Targeting miR-130b-3p mediated pathological communication between dysfunctional adipocytes and cardiomyocytes may be a novel strategy attenuating diabetic exacerbation of MI/R injury.

Indexed as

AdipocytesAnimalsDiabetes Mellitus, ExperimentalHumansMaleMiceMyocardial Reperfusion InjuryMyocytes, Cardiacapoptosisdiabetes mellitusextracellular vesiclesischemia-reperfusion injurymicroRNA

Identifiers

PMID31918577
PMCPMC7093230
OpenAlexW3000160763

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.